US Patent 11352361 Compounds useful as RET inhibitors
Patent 11352361 was granted and assigned to Cancer Research Technology Limited on June, 2022 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
April 13, 2018
Date of Patent
June 7, 2022
Patent Applicant
Patent Application Number
16604332
Patent Citations Received
Patent Inventor Names
Rebecca Newton
0
Allan Jordan
0
Bohdan Waszkowycz
0
George Hynd
0
Jonathan Mark Sutton
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11352361 Compounds useful as RET inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
